CoChat
Sign Up
Cited by 270

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study

Langsted, Anne, Kamstrup, Pia R, Benn, Marianne, Tybjærg-Hansen, Anne, Nordestgaard, Børge G·2016·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(16)30042-0
Open this paper in CoChat — free account

Abstract

Background The reason why lipoprotein(a) concentrations are raised in individuals with clinical familial hypercholesterolaemia is unclear. We tested the hypotheses that high lipoprotein(a) cholesterol and LPA risk genotypes are a possible cause of clinical familial hypercholesterolaemia, and that individuals with both high lipoprotein(a) concentrations and clinical familial hypercholesterolaemia have the highest risk of myocardial infarction. Methods We did a prospective cohort study that included data from 46 200 individuals from the Copenhagen General Population Study who had lipoprotein(a) measurements and were genotyped for common familial hypercholesterolaemia mutations. Individuals receiving cholesterol-lowering drugs had their concentrations of LDL and total cholesterol multiplied by 1·43, corresponding to an estimated 30% reduction in LDL cholesterol from the treatment. In lipoprotein(a) cholesterol-adjusted analyses, total cholesterol and LDL cholesterol were adjusted for the lipoprotein(a) cholesterol content by subtracting 30% of the individuals' lipoprotein(a) total mass before total and LDL cholesterol were used for diagnosis of clinical familial hypercholesterolaemia. We used modified Dutch Lipid Clinic Network (DLCN), Simon Broome, and Make Early Diagnosis to Prevent Early Death (MEDPED) criteria to clinically diagnose familial hypercholesterolaemia. Cox proportional hazard regression calculated hazard ratios (95% CI) of myocardial infarction. Findings Using un…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(16)30042-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 26

  1. Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 · DOI · Paper page
  2. Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 · DOI · Paper page
  3. Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 · DOI · Paper page
  4. Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273 · DOI · Paper page
  5. Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur Heart J, 35, 2146, 10.1093/eurheartj/ehu274 · DOI · Paper page
  6. Wiklund, 1990, Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia, Lancet, 335, 1360, 10.1016/0140-6736(90)91242-3 · DOI
  7. Guo, 1991, Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype, Atherosclerosis, 86, 69, 10.1016/0021-9150(91)90100-H · DOI
  8. Lingenhel, 1998, Concentrations of the atherogenic Lp(a) are elevated in FH, Eur J Hum Genet, 6, 50, 10.1038/sj.ejhg.5200152 · DOI · Paper page
  9. Stein, 2014, Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, Eur Heart J, 35, 2249, 10.1093/eurheartj/ehu085 · DOI · Paper page
  10. Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 · DOI · Paper page
  11. Kamstrup, 2014, Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, J Am Coll Cardiol, 63, 470, 10.1016/j.jacc.2013.09.038 · DOI · Paper page
  12. Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 · DOI
  13. Kinpara, 2011, Lipoprotein(a)-cholesterol: a significant component of serum cholesterol, Clin Chim Acta, 412, 1783, 10.1016/j.cca.2011.05.036 · DOI
  14. Watts, 2011, Familial hypercholesterolaemia: a model of care for Australasia, Atheroscler Suppl, 12, 221, 10.1016/j.atherosclerosissup.2011.06.001 · DOI
  15. 1991, Risk of fatal coronary heart disease in familial hypercholesterolaemia, BMJ, 303, 893, 10.1136/bmj.303.6807.893 · DOI · Paper page
  16. Williams, 1993, Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics, Am J Cardiol, 72, 171, 10.1016/0002-9149(93)90155-6 · DOI · Paper page
  17. Benn, 2016, Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217, Eur Heart J, 37, 1384, 10.1093/eurheartj/ehw028 · DOI
  18. Talmud, 2013, Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study, Lancet, 381, 1293, 10.1016/S0140-6736(12)62127-8 · DOI
  19. Kolski, 2012, Emerging therapeutic agents to lower lipoprotein (a) levels, Curr Opin Lipidol, 23, 560, 10.1097/MOL.0b013e3283598d81 · DOI
  20. Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J Clin Invest, 95, 1403, 10.1172/JCI117794 · DOI · Paper page
  21. Alonso, 2014, Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation, J Am Coll Cardiol, 63, 1982, 10.1016/j.jacc.2014.01.063 · DOI · Paper page
  22. Tybjaerg-Hansen, 2005, Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations, Arterioscler Thromb Vasc Biol, 25, 211, 10.1161/01.ATV.0000149380.94984.f0 · DOI
  23. Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J Biol Chem, 290, 1649, 10.1074/jbc.M114.611988 · DOI · Paper page
  24. Seed, 1990, Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia, N Engl J Med, 322, 1494, 10.1056/NEJM199005243222104 · DOI
  25. Jansen, 2004, The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients, J Intern Med, 256, 482, 10.1111/j.1365-2796.2004.01405.x · DOI
  26. Holmes, 2005, Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia, Clin Chem, 51, 2067, 10.1373/clinchem.2005.055228 · DOI

Cited by

Sorted by citations

See all 270

Metadata

Authors
Langsted, A., Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2016-07
Volume
4
Issue
7
Pages
577-587
ISSN
2213-8587
DOI
10.1016/s2213-8587(16)30042-0
Cited by
270
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review